Barclays Initiates Coverage of Inspire Medical Systems at Underweight
Fintel reports that on October 7, 2026, Barclays initiated coverage of Inspire Medical Systems (NYSE:INSP) (DB:2DR) with a Underweight recommendation.
Inspire Medical Systems, Inc., based in the United States, operates within the healthcare sector, specifically focusing on medical devices designed for the treatment of obstructive sleep apnea (OSA). The company commercializes the Inspire therapy system, which is an FDA-approved, implantable device offering an alternative to traditional CPAP machines. Prior to the rating action, the stock closed at $68.20 on October 6, 2026. This latest close represents a one-week price change of -6.81% from a baseline close of $73.18 on September 29, 2026, and a one-month price change of +8.12% from a baseline close of $63.08 on September 4, 2026.
As of October 2, 2026, the current consensus target mean for the company was $71.53, with a median target of $61.20, representing an implied change of +4.88%. This is compared to the prior consensus target mean of $69.55 recorded on September 15, 2026, reflecting a consensus target revision of +2.84%. For the current recommendation period of September 1, 2026, the aggregate analyst sentiment showed 4 strong buy, 5 buy, 13 hold, and 2 sell recommendations, totaling 24 recommendations. This breakdown represents 37.5% positive, 54.2% hold, and 8.3% negative recommendations. In the prior recommendation period of August 1, 2026, there were 3 strong buy, 6 buy, 13 hold, and 2 sell recommendations.
Other recent analyst actions include Freedom Capital Markets maintaining a Buy rating on October 2, 2026, and RBC Capital maintaining a Sector Perform rating on October 1, 2026. Earlier, Freedom Capital Markets maintained a Buy rating on September 21, 2026, and Stifel maintained a Buy rating on September 11, 2026. In its latest earnings report on August 3, 2026, Inspire Medical Systems reported actual earnings per share of 0.01, compared to the estimated earnings per share of -0.2764. The company reported actual revenue of $200,581,000.00, exceeding the estimated revenue of $198,564,042.00. The company's upcoming earnings date is scheduled for November 2, 2026, during the amc session.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Underweight | initiated coverage | |
| October 2, 2026 | Freedom Capital Markets | Buy | Buy | maintained |
| October 1, 2026 | RBC Capital | Sector Perform | Sector Perform | maintained |
| September 21, 2026 | Freedom Capital Markets | Buy | Buy | maintained |
| September 11, 2026 | Stifel | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.